403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Oncolytics Biotech Inc
(MENAFN- Baystreet) 10:12 AM EST - Oncolytics Biotech Inc: Announced alignment with the U.S. Food and Drug Administration regarding the design of its pivotal study of pelareorep in combination with standard-of-care therapy for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC). Oncolytics Biotech Inc
shares N are trading up one cent at $1.04.
Full Press Release:
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment